---
title: Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
nct_id: NCT06017271
overall_status: WITHDRAWN
sponsor: "First Affiliated Hospital Xi'an Jiaotong University"
study_type: OBSERVATIONAL
primary_condition: Pulmonary Embolism
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06017271.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06017271"
ct_last_update_post_date: 2024-07-22
last_seen_at: "2026-05-12T07:21:29.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer

**NCT ID:** [NCT06017271](https://clinicaltrials.gov/study/NCT06017271)

## Key Facts

- **Status:** WITHDRAWN
- **Why Stopped:** The number of patients is not sufficient to support the project.
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 0
- **Lead Sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Conditions:** Pulmonary Embolism, Lung Cancer
- **Start Date:** 2024-05-01
- **Completion Date:** 2024-07-19
- **CT.gov Last Update:** 2024-07-22

## Brief Summary

The occurrence and progression of lung cancer is related to visceral adipose tissue (VAT). Epicardial adipose tissue (EAT) is a kind of VAT, producing a variety of inflammatory cytokines and adipokines, participating in the formation of local inflammation, promoting the formation of pre-thrombotic state, and leading to the occurrence of thromboembolism. Patients with lung cancer have increased inflammatory response and are more prone to suffer thrombosis. However, in lung cancer patients, the clinical correlation between EAT and pulmonary embolism has not been reported. Objective: To analyze the risk factors of poor prognosis in lung cancer patients with PE, and to explore the predictive value of EAT in pulmonary embolism events and death in lung cancer patients. Methods: EAT volume and density, as well as anthropometric and blood biomarkers, were evaluated in a sample of lung cancer patients, half with pulmonary embolism and half without. The incidence of adverse prognosis and related factors were followed up by telephone.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 70 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* The pathological diagnosis was lung cancer
* Pulmonary artery was evaluated by CTA during hospitalization.

Exclusion Criteria:

* Patients with incomplete clinical data
* Patients with no follow-up data
* Patients with a history of PE before diagnosis of lung cancer
```

## Arms

- **PE group** — The CTPA diagnosis suggest pulmonary embolism
- **control group** — The CTPA diagnosis did not suggest pulmonary embolism

## Interventions

- **CTPA (computed tomography pulmonary angiography)** (DIAGNOSTIC_TEST) — The CTPA diagnosis suggest or did not suggest pulmonary embolism.

## Primary Outcomes

- **EAT volume** _(time frame: May, 20, 2023)_ — volume of epicardial adipose tissue (EAT), Cm3
- **EAT density** _(time frame: May, 20, 2023)_ — density of epicardial adipose tissue (EAT) , Hounsfield Units (HU)

## Locations (1)

- First Affiliated Hospital of Xian Jiaotong University, Xi'an, Shaanxi, China

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.first affiliated hospital of xian jiaotong university|xi'an|shaanxi|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06017271.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06017271*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*